GlassScriptPhysician profile
Bridget K Shannon
NPI 1063898492
$5,735.74
in general payments reported to CMS, 2019-2025
25 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,762 · 2022: $1,370 · 2023: $464 · 2024: $1,043 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $913.00 | 2021-2025 | Lifevest |
| Amgen INC. | $668.57 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.02 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $476.12 | 2021-2024 | Xarelto |
| Pfizer INC. | $383.80 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $358.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $345.84 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $304.31 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $261.65 | 2021-2025 | Lokelma, Bevespi Aerosphere |
| Boston Scientific Corporation | $222.09 | 2021-2025 | Watchman Flx |
| Abbott Laboratories | $221.09 | 2021-2025 | Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $213.02 | 2021-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $136.96 | 2025 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $126.68 | 2024-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Medtronic, INC. | $126.21 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $90.35 | 2021-2022 | |
| Novo Nordisk INC | $70.17 | 2021-2022 | |
| Amarin Pharma, INC. | $49.56 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.89 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $34.06 | 2023-2024 | Inpefa |
| Biotronik INC. | $23.68 | 2021 | |
| Astellas Pharma US INC | $19.96 | 2021 | |
| Esperion Therapeutics, INC. | $16.54 | 2021 | |
| Cardiovascular Systems INC. | $15.59 | 2022 | |
| Cvrx, INC. | $15.40 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.